CIA
ASMB icon

Capital Impact Advisors’s Assembly Biosciences ASMB Stock Holding History

Capital Impact Advisors’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,033
Closed -$1.65M – 121
2019
Q2 		$1.65M Sell
1,033
-4,707
-82% -$895K 0.6% 95
2019
Q1 		$1.52M Hold
5,740
– – 0.68% 79
2018
Q4 		$1.52M Buy
5,740
+1,824
+47% +$528K 0.65% 82
2018
Q3 		$1.75M Buy
3,916
+526
+16% +$246K 0.6% 92
2018
Q2 		$1.6M Buy
3,390
+735
+28% +$389K 0.59% 102
2018
Q1 		$1.57M Buy
+2,655
New +$1.65M 0.64% 72

Other funds holding ASMB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital Impact Advisors's ASMB Position: Q3 2019 in Review

Capital Impact Advisors sold out of Assembly Biosciences (ASMB) in Q3 2019, closing a stake of 1,033 shares — an estimated $1.65M sold.

Capital Impact Advisors first reported a position in ASMB in Q1 2018 and held it in 6 quarters. The position peaked at $1.75M in Q3 2018. 98 funds tracked by Wall St. Rank hold ASMB as of Q3 2019.

  • Capital Impact Advisors reported no remaining Assembly Biosciences position as of Q3 2019 after selling out during the quarter.
  • Capital Impact Advisors sold 1,033 Assembly Biosciences shares in Q3 2019, an estimated $1.65M.
  • Capital Impact Advisors first reported a position in Assembly Biosciences in Q1 2018 and held it in 6 quarters.
  • Capital Impact Advisors's Assembly Biosciences position peaked at $1.75M in Q3 2018.
  • 98 funds tracked by Wall St. Rank held Assembly Biosciences as of Q3 2019.

Based on Capital Impact Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.